Analyst consensus rating
Oncolytics Biotech Analyst Rating: Buy
Direct answer
Oncolytics Biotech's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.42.
Forecast evidence checked November 17, 2026.
Get free Oncolytics Biotech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.34
- Average price target
- $4.42
- High price target
- $5.82
- Low price target
- $2.83
- Low target gap
- +733.2%
- Target upside
- +1,200.8%
- High target gap
- +1,613.7%
- Target range width
- 880.5%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- November 17, 2026
- Valid through
- November 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Oncolytics Biotech?
Oncolytics Biotech has a verified Buy consensus. The same dataset has an average price target of $4.42.
How far are Oncolytics Biotech's low and high targets from the recorded price?
The low target implies +733.2%, while the high target implies +1,613.7%.
How many analysts are included in Oncolytics Biotech's consensus?
The verified consensus includes 5 analysts.
How is Oncolytics Biotech's target upside or downside calculated?
The average target of $4.42 is divided by the recorded price of $0.34, then one is subtracted to produce +1,200.8%. This does not guarantee a future return.
When was Oncolytics Biotech's analyst forecast verified?
The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.